Nikko Asset Management Americas Inc. Raises Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Nikko Asset Management Americas Inc. boosted its position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 42.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 789,222 shares of the company’s stock after buying an additional 236,620 shares during the quarter. Nikko Asset Management Americas Inc. owned approximately 1.04% of Nurix Therapeutics worth $14,869,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. US Bancorp DE boosted its stake in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company’s stock worth $27,000 after buying an additional 842 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Nurix Therapeutics by 30.6% during the third quarter. Amalgamated Bank now owns 2,182 shares of the company’s stock valued at $49,000 after purchasing an additional 511 shares during the period. Quarry LP boosted its stake in shares of Nurix Therapeutics by 3,746.2% during the third quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $56,000 after purchasing an additional 2,435 shares during the period. Quest Partners LLC boosted its stake in shares of Nurix Therapeutics by 21.3% during the third quarter. Quest Partners LLC now owns 7,458 shares of the company’s stock valued at $168,000 after purchasing an additional 1,312 shares during the period. Finally, Bellevue Group AG purchased a new stake in shares of Nurix Therapeutics during the third quarter valued at approximately $180,000.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total value of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares of the company’s stock, valued at $488,660.76. The trade was a 14.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of Nurix Therapeutics stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $73,246.50. Following the completion of the transaction, the insider now directly owns 55,937 shares of the company’s stock, valued at approximately $1,110,349.45. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 12,326 shares of company stock valued at $213,449 in the last quarter. 7.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

NRIX has been the subject of a number of analyst reports. Stifel Nicolaus increased their price objective on Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. HC Wainwright increased their price objective on Nurix Therapeutics from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Morgan Stanley increased their price objective on Nurix Therapeutics from $16.00 to $17.00 and gave the company an “equal weight” rating in a research note on Monday, February 3rd. Needham & Company LLC decreased their target price on Nurix Therapeutics from $29.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Stephens restated an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a report on Tuesday, January 21st. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $31.81.

Nurix Therapeutics Trading Up 3.0 %

Shares of Nurix Therapeutics stock opened at $13.59 on Monday. The firm has a market capitalization of $1.03 billion, a P/E ratio of -4.70 and a beta of 2.18. The business has a fifty day simple moving average of $17.54 and a two-hundred day simple moving average of $21.14. Nurix Therapeutics, Inc. has a 12 month low of $11.90 and a 12 month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last announced its quarterly earnings data on Tuesday, January 28th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.08). Nurix Therapeutics had a negative net margin of 354.85% and a negative return on equity of 53.65%. Analysts predict that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.